KLRK1 and neoplasm: For instance, tumor-derived sMIC-A could bind to membrane-bound NKG2D receptors, thereby blocking the activation of NKG2D pathways, inhibiting the cytotoxicity of NK and T cells against tumor cells [57, 168].